Antiphospholipid Syndrome (APS)
Also known as: Hughes Syndrome, Anticardiolipin Syndrome, Lupus Anticoagulant Syndrome
Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by the presence of antiphospholipid antibodies (aPL) in the blood, which leads to an increased risk of blood clots (thrombosis) in arteries and veins, as well as pregnancy complications such as recurrent miscarriages, premature births, and stillbirths. APS can occur as a primary condition or in association with other autoimmune diseases, most notably systemic lupus erythematosus (SLE).
Imagine your body's security system is confused and starts attacking your own blood, making it sticky and causing clots. This can lead to problems like strokes, miscarriages, and other health issues. Doctors use special medicines to thin your blood and prevent these clots.
Signs & Symptoms
- Blood clots in legs (deep vein thrombosis)
- Blood clots in lungs (pulmonary embolism)
- Stroke
- Transient ischemic attack (TIA)
- Recurrent miscarriages
- Premature birth
- Stillbirth
- Livedo reticularis (a lace-like skin rash)
- Thrombocytopenia (low platelet count)
- Migraines
- Seizures
- Cognitive dysfunction
- Heart valve abnormalities
Treatment Options
Anticoagulants (Warfarin, Heparin, Direct Oral Anticoagulants)
HIGHLY EFFECTIVEAntiplatelet agents (Aspirin)
MODERATELY EFFECTIVEHydroxychloroquine
MODERATELY EFFECTIVEIntravenous Immunoglobulin (IVIG)
MODERATELY EFFECTIVERituximab
MODERATELY EFFECTIVEManagement of pregnancy complications (Low-dose aspirin and heparin)
HIGHLY EFFECTIVEDiagnosis
- Clinical evaluation
- Antiphospholipid antibody testing (anticardiolipin antibodies, anti-beta2 glycoprotein I antibodies, lupus anticoagulant)
- Complete blood count (CBC)
- Coagulation studies (prothrombin time, partial thromboplastin time)
- Imaging studies (ultrasound, CT scan, MRI) to detect blood clots
History
Antiphospholipid antibodies were first described in the context of false-positive syphilis serological tests in patients with systemic lupus erythematosus (SLE). In 1983, Dr. Graham Hughes recognized the association between these antibodies and thrombosis and pregnancy complications, leading to the formal description of antiphospholipid syndrome.
Recent Breakthroughs
Targeting Complement Activation in APS
Research suggests that complement activation plays a significant role in the pathogenesis of APS. Studies are exploring the potential of complement inhibitors as a novel therapeutic approach.
New Insights into the Role of B Cells in APS
Recent studies have highlighted the importance of B cells in the production of aPL antibodies and the development of APS. This has led to renewed interest in B cell-targeted therapies, such as rituximab and belimumab.
Novel Oral Anticoagulants (NOACs) in APS
Ongoing clinical trials are evaluating the efficacy and safety of direct oral anticoagulants (DOACs) compared to warfarin in patients with APS, particularly those with arterial thrombosis. Preliminary results suggest that DOACs may be a viable alternative for some patients, but further research is needed.